Academic Journal
Q1Pharmacological Reviews
About Pharmacological Reviews
Pharmacological Reviews is a scholarly journal published by Elsevier Inc.. SCImago 2025 places it in Q1 with an SJR of 4.967 and an H-index of 273.
Its listed coverage is 1949, 1951-2026 and its research categories include Molecular Medicine (Q1); Pharmacology (Q1). The 2025 dataset reports 76 documents and 2372 citations across the latest three-year reporting window.
Pharmacological Reviews is one of the most prestigious and highly cited journals in the field of pharmacology and pharmaceutical sciences. Published by the American Society for Pharmacology and Experimental Therapeutics (ASPET), this peer-reviewed journal is renowned for its comprehensive, authoritative review articles that explore emerging and established topics in pharmacology, drug development, and therapeutics.
What Is Pharmacological Reviews?
Founded in 1949, Pharmacological Reviews provides in-depth analyses of a wide range of pharmacological topics, including drug action, mechanisms, therapeutic uses, and adverse effects. The journal's articles are not standard research papers but rather expert reviews that synthesize vast amounts of scientific literature. These articles help scientists, healthcare professionals, and students understand complex pharmacological issues and stay up-to-date with recent advancements.
Why Pharmacological Reviews Is Important
Pharmacological Reviews plays a critical role in the scientific community for several reasons:
-
Authoritative Content: Articles are written by leading experts in their respective fields, ensuring high-quality, accurate, and well-researched information.
-
Educational Resource: With its in-depth reviews, the journal is an invaluable tool for graduate students, educators, and researchers seeking to understand the nuances of pharmacological science.
-
Impactful Research: It has one of the highest impact factors among pharmacology journals, reflecting the wide reach and significance of its published content.
-
Advancing Drug Development: By summarizing the latest findings, Pharmacological Reviews supports pharmaceutical research, drug discovery, and the development of new therapies.
Key Topics Covered
The journal covers a broad spectrum of pharmacological disciplines, including:
-
Molecular and cellular pharmacology
-
Neuropharmacology and psychopharmacology
-
Cardiovascular and respiratory pharmacology
-
Endocrine and metabolic pharmacology
-
Toxicology and drug safety
-
Pharmacokinetics and drug metabolism
-
Translational and clinical pharmacology
Target Audience
Pharmacological Reviews is tailored for pharmacologists, toxicologists, clinicians, researchers, pharmaceutical scientists, and healthcare professionals. Its content is especially useful for those involved in drug design, clinical trials, and therapeutic innovation. Additionally, it serves as a foundational reference for academic instructors and students in medical and pharmacy schools.
Accessibility and Publication Frequency
The journal is published quarterly and is available both in print and online through ASPET’s website. Subscribers have access to an archive of decades’ worth of high-impact review articles, making it a goldmine of information for researchers and professionals alike.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Scop Pharmacological Reviews stands at the forefront of scholarly publishing in the field of pharmacology and pharmaceutical sciences. As a leading platform dedicated to delivering high-quality, peer-reviewed content, Scop Pharmacological Reviews provides valuable insights into drug mechanisms, pharmacodynamics, pharmacokinetics, toxicology, and emerging therapeutics. Researchers, clinicians, and academic professionals turn to Scop for authoritative and up-to-date reviews that inform practice and fuel future innovations in medicine.
Comprehensive Pharmacological Insights
Each review published by Scop Pharmacological Reviews is meticulously curated and written by subject matter experts with extensive experience in pharmacological research. The journal covers a wide range of topics including:
-
Mechanisms of drug action
-
Novel therapeutic agents
-
Drug interactions and side effects
-
Molecular and cellular pharmacology
-
Advances in neuropharmacology, cardiovascular pharmacology, and more
These reviews serve as essential references for professionals seeking a deeper understanding of complex pharmacological concepts and the latest scientific breakthroughs.
Peer-Reviewed and High Impact
Quality is at the core of Scop Pharmacological Reviews. All submitted articles undergo a rigorous peer-review process to ensure scientific accuracy, relevance, and originality. This commitment to excellence has made Scop a respected name in the global scientific community.
Moreover, the journal aims to boost the visibility of its authors by optimizing content for academic citations, indexing in major scientific databases, and maintaining a strong digital presence. This contributes to the journal’s high impact and growing readership among pharmacologists, toxicologists, and healthcare professionals worldwide.
SEO Optimization for Greater Reach
In today’s digital age, accessibility and discoverability are crucial. Scop Pharmacological Reviews leverages search engine optimization (SEO) techniques to ensure that its articles rank highly in Google and other search engines. By incorporating targeted keywords such as pharmacological reviews, drug mechanisms, clinical pharmacology, and therapeutic advances, Scop ensures that users searching for pharmacology-related content can easily find relevant and reliable information.
Whether you are a researcher looking for the latest developments in drug therapy, a student studying for pharmacology exams, or a healthcare provider seeking evidence-based information, Scop offers a wealth of knowledge at your fingertips.
Join a Thriving Scientific Community
Scop Pharmacological Reviews also invites contributions from researchers across the globe. By publishing with Scop, authors gain access to a broad audience, robust editorial support, and the opportunity to impact the future of medicine. Submissions are open year-round, and authors can benefit from timely feedback and guidance throughout the review process.
Recent Research Articles
Latest publications matched automatically by ISSN.
Recent advances in methotrexate pharmacology and potential therapeutic uses in age-related cardiometabolic and neurodegenerative diseases
Arduino A. Mangoni, Julie-Ann Hulin, Sara Tommasi
2026-09 · DOI: 10.1016/j.pharmr.2026.100147Chronic pain in Alzheimer disease and the role of neuroimmune interactions
Marzia Malcangio, George Sideris-Lampretsas
2026-09 · DOI: 10.1016/j.pharmr.2026.100149Exploration of multifunctional characteristics and regulatory mechanism of promoter G-quadruplexes
Ziyi Zhao, Yangzi Zhang, Jingjing Tian, Yuan Su et al.
2026-09 · DOI: 10.1016/j.pharmr.2026.100151The Promise of Biased Ligands in Therapeutics
Dylan S. Eiger, Jeffrey S. Smith, Sudarshan Rajagopal
2026-09 · DOI: 10.1016/j.pharmr.2026.100160Hunting gremlins: GREM1 as a new therapeutic target for multiple diseases including glaucoma
David P. Siderovski, Nishanth Myneni, Monica Botross, Pinkal D. Patel et al.
2026-09 · DOI: 10.1016/j.pharmr.2026.100152Renal aging and associated diseases: Common mechanisms and therapeutic approaches
Jabir Aliyu Muhammad, Nadya Marcelina Julianto, Tania Setiawan, Teresa Fiona Fadjaray et al.
2026-09 · DOI: 10.1016/j.pharmr.2026.100148Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Zara Siu Wa Chui, Yaqian Xue, Xiaoping Wu, Aimin Xu et al.
2026-09 · DOI: 10.1016/j.pharmr.2026.100150Regulation of the Mineralocorticoid Receptor in Physiology and Disease
Morag J. Young, Peter J. Fuller, Onno C. Meijer, Timothy J. Cole et al.
2026-08 · DOI: 10.1016/j.pharmr.2026.100156Application of human liver cell models in drug development and toxicity studies – the role of membrane transporters
Edit Szabó, Ágnes Telbisz, Zsuzsa Erdei, Kiara Gitta Farkas et al.
2026-08 · DOI: 10.1016/j.pharmr.2026.100157Recombinant protein drug metabolism and pharmacokinetics
Jie-Bing Jiang, Huan-Yu Zhao, Zhu-Wei Miao, Chao-Yu Miao et al.
2026-08 · DOI: 10.1016/j.pharmr.2026.100155Harnessing autophagy and its transcriptional regulation in tumorigenesis and neurodegeneration: Potential and existing therapeutic strategies
Parul Suri, Abel B. Daartey, D.M. Isha Olive Khan, Naga Pradeep Rayana et al.
2026-08 · DOI: 10.1016/j.pharmr.2026.100158GPCR Signaling From A Primary Cilium Perspective
Olof Idevall-Hagren, Jing Hughes
2026-08 · DOI: 10.1016/j.pharmr.2026.100159Vein graft failure: Pathophysiology, detection, prevention and emerging therapeutic strategies
Simon D. Brown, Sandra Sanchez-Esteban, Laura Clark, Katarina Miteva et al.
2026-07 · DOI: 10.1016/j.pharmr.2026.100139Mast cell proteases and their significance in physiology, pathology, and therapeutic approaches
Afshin Derakhshani, Leela Mahajan, Kyle Lesack, Navid Saranjam et al.
2026-07 · DOI: 10.1016/j.pharmr.2026.100144Erratum to “Links between COVID-19, long COVID, and neurodegeneration: The role of glycosphingolipids” [Pharmacological Reviews 78 (2026) 100113]
Michael Spedding, Johannes Aerts, Steve Alexander, Aurélie-Gaëlle Bellozzi Woestelandt et al.
2026-07 · DOI: 10.1016/j.pharmr.2026.100142Are we underestimating the benefits of lipid-lowering therapies?
Angela Pirillo, Manuela Casula, Elena Olmastroni, Stefano Scotti et al.
2026-07 · DOI: 10.1016/j.pharmr.2026.100140Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions
Maria K. Smatti, Zainab Jan, Hadi M. Yassine
2026-07 · DOI: 10.1016/j.pharmr.2026.100136Kv7 channels as pharmacological targets for CNS diseases
Francesco Miceli, Maria Virginia Soldovieri, Vincenzo Barrese, Maurizio Taglialatela et al.
2026-07 · DOI: 10.1016/j.pharmr.2026.100153Reharnessing the therapeutic potential of gallium-based compounds in oncology: From the laboratory to the clinic
Christopher R. Chitambar, Casey J. Zoss, Mona M. Al-Gizawiy, Kathleen M. Schmainda et al.
2026-07 · DOI: 10.1016/j.pharmr.2026.100138Translational medications development for methamphetamine use disorder: A systematic review of preclinical, human laboratory, and clinical research
Alexandra N. Johansen, Mark A. Smith, William W. Stoops
2026-07 · DOI: 10.1016/j.pharmr.2026.100145Reviews
Community Reviews
Version History
April 20, 2025 at 11:55 am
April 20, 2025